136 related articles for article (PubMed ID: 31695173)
1. Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Domingo-Domènech E; Boumendil A; Climent F; Socié G; Kroschinsky F; Finel H; Vandenbergue E; Nemet D; Stelljes M; Bittenbring JT; Robinson S; Montoto S; Sureda A; Dreger P;
Bone Marrow Transplant; 2020 Mar; 55(3):633-640. PubMed ID: 31695173
[TBL] [Abstract][Full Text] [Related]
2. Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT.
Domingo-Domènech E; Boumendil A; Climent F; Sengeloev H; Wahlin B; Wattad W; Arat M; Finel H; Schapp N; Ganser A; Yeshurun M; Pavone V; Snowden J; Finke J; Montoto S; Sureda A; Dreger P;
Bone Marrow Transplant; 2020 Apr; 55(4):796-803. PubMed ID: 31695174
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Furqan F; Ahn KW; Chen Y; Kaur M; Abutalib SA; Ahmed N; Ahmed S; Kharfan-Dabaja MA; Friedberg J; Gregory T; Hill L; Sterling C; Barta SK; Shadman M; Perales MA; Zain J; Herrera AF; Sauter C; Hamadani M
Br J Haematol; 2023 Jan; 200(1):54-63. PubMed ID: 36120837
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.
Chen R; Palmer JM; Thomas SH; Tsai NC; Farol L; Nademanee A; Forman SJ; Gopal AK
Blood; 2012 Jun; 119(26):6379-81. PubMed ID: 22611160
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A
Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
8. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Ortí G; Gras L; Zinger N; Finazzi MC; Sockel K; Robin M; Forcade E; Avenoso D; Kröger N; Finke J; Radujkovic A; Hunault-Berger M; Schroyens W; Zuckerman T; Bourhis JH; Chalandon Y; Bloor A; Schots R; de Wreede LC; Drozd-Sokolowska J; Raj K; Polverelli N; Czerw T; Hernández-Boluda JC; McLornan D; Yakoub-Agha I
Am J Hematol; 2023 Apr; 98(4):628-638. PubMed ID: 36606718
[TBL] [Abstract][Full Text] [Related]
10. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
[TBL] [Abstract][Full Text] [Related]
13. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
Koh KN; Im HJ; Suh JK; Lee SW; Choi ES; Seo JJ
Pediatr Blood Cancer; 2015 Jun; 62(6):1063-5. PubMed ID: 25641881
[TBL] [Abstract][Full Text] [Related]
14. Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents.
Faisal MS; Hanel W; Voorhees T; Li R; Huang Y; Khan A; Bond D; Sawalha Y; Reneau J; Alinari L; Baiocchi R; Christian B; Maddocks K; Efebera Y; Penza S; Saad A; Brammer J; DeLima M; Jaglowski S; Epperla N
Cancer Med; 2023 Apr; 12(7):8228-8237. PubMed ID: 36653918
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
16. Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma.
Fukano R; Mori T; Fujita N; Kobayashi R; Mitsui T; Kato K; Suzuki R; Suzumiya J; Fukuda T; Shindo M; Maseki N; Shimoyama T; Okada K; Inoue M; Inagaki J; Hashii Y; Sato A; Tabuchi K
Int J Hematol; 2019 Dec; 110(6):723-728. PubMed ID: 31620968
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.
Carlo-Stella C; Ricci F; Dalto S; Mazza R; Malagola M; Patriarca F; Viviani S; Russo D; Giordano L; Castagna L; Corradini P; Santoro A
Oncologist; 2015 Mar; 20(3):323-8. PubMed ID: 25669663
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.
Pemmaraju N; Tanaka MF; Ravandi F; Lin H; Baladandayuthapani V; Rondon G; Giralt SA; Chen J; Pierce S; Cortes J; Kantarjian H; Champlin RE; De Lima M; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):485-92. PubMed ID: 23769669
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China.
Liu J; Zheng L; Chuang LH
J Med Econ; 2022; 25(1):99-107. PubMed ID: 34927526
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Domingo-Domenech E; Duarte RF; Boumedil A; Onida F; Gabriel I; Finel H; Arcese W; Browne P; Beelen D; Kobbe G; Veelken H; Arranz R; Greinix H; Lenhoff S; Poiré X; Ribera JM; Thompson J; Zuckerman T; Mufti GJ; Cortelezzi A; Olavarria E; Dreger P; Sureda A; Montoto S
Bone Marrow Transplant; 2021 Jun; 56(6):1391-1401. PubMed ID: 33420392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
